CD19 and B-cell chronic lymphocytic leukemia: While we observed higher leukocyte counts for the CLL8 discovery cohort of CD19 sorted CLL cases, likely through the selection of samples with abundant material for multiple analyses, patient characteristics and especially high-risk markers showed a well-balanced distribution representative of the full trial population.